- Home
- SYBX vs NRXP Comparison
SYBX vs NRXP Comparison
Compare SYBX & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYBX
- NRXP
- Stock Information
- Founded
- SYBX N/A
- NRXP 2015
- Country
- SYBX United States
- NRXP United States
- Employees
- SYBX N/A
- NRXP N/A
- Industry
- SYBX Biotechnology: Pharmaceutical Preparations
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- SYBX Health Care
- NRXP Health Care
- Exchange
- SYBX Nasdaq
- NRXP Nasdaq
- Market Cap
- SYBX 17.0M
- NRXP 14.8M
- IPO Year
- SYBX N/A
- NRXP N/A
- Fundamental
- Price
- SYBX $1.42
- NRXP $1.50
- Analyst Decision
- SYBX Hold
- NRXP Strong Buy
- Analyst Count
- SYBX 3
- NRXP 3
- Target Price
- SYBX $1.00
- NRXP $31.67
- AVG Volume (30 Days)
- SYBX 74.6K
- NRXP 317.1K
- Earning Date
- SYBX 11-12-2024
- NRXP 11-14-2024
- Dividend Yield
- SYBX N/A
- NRXP N/A
- EPS Growth
- SYBX N/A
- NRXP N/A
- EPS
- SYBX N/A
- NRXP N/A
- Revenue
- SYBX $2,777,000.00
- NRXP N/A
- Revenue This Year
- SYBX N/A
- NRXP N/A
- Revenue Next Year
- SYBX N/A
- NRXP N/A
- P/E Ratio
- SYBX N/A
- NRXP N/A
- Revenue Growth
- SYBX 292.23
- NRXP N/A
- 52 Week Low
- SYBX $1.22
- NRXP $1.10
- 52 Week High
- SYBX $5.12
- NRXP $7.33
- Technical
- Relative Strength Index (RSI)
- SYBX 48.54
- NRXP 61.95
- Support Level
- SYBX $1.36
- NRXP $1.17
- Resistance Level
- SYBX $1.88
- NRXP $1.85
- Average True Range (ATR)
- SYBX 0.09
- NRXP 0.13
- MACD
- SYBX -0.01
- NRXP 0.04
- Stochastic Oscillator
- SYBX 11.54
- NRXP 50.00
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.